A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
Scott L. Friedman(Icahn School of Medicine at Mount Sinai), Éric Lefebvre(Pinnacle Clinical Research), Pamela Vig(Pinnacle Clinical Research), Zachary Goodman(Inova Fairfax Hospital), Brian L. Wiens(Pinnacle Clinical Research), Rohit Loomba(University of California San Diego), Juan Caballería(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Star Seyedkazemi(Pinnacle Clinical Research), Liza Melchor‐Khan(Pinnacle Clinical Research), Arun J. Sanyal(Virginia Commonwealth University), Sven Francque(Inova Health System), Vlad Ratziu(Inserm), Jeffrey Vest(Medpace (United States)), Frank Tacke(Charité - Universitätsmedizin Berlin), Guruprasad P. Aithal(NIHR Nottingham Digestive Diseases Biomedical Research Unit), Kris V. Kowdley(Liver Institute Northwest), Stephen A. Harrison(Pinnacle Clinical Research), Antonio Craxı̀(University of Palermo), Vincent Wai‐Sun Wong(Chinese University of Hong Kong), Laurent Fischer(Pinnacle Clinical Research), Krzysztof Simon(Wroclaw Medical University), Geoffrey C. Farrell(Australian National University), Manal F. Abdelmalek(Mayo Clinic)
Cited by 657
Related Papers
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
|Hepatology|2017|7.2k
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k